Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1286.029
- +7.900+0.62%
Close Jan 2 16:00 ET
1297.200High1277.159Low
1286.305Open1278.129Pre Close26.79MVolume8Rise62.84P/E (Static)850.86MTurnover--Flatline2.14%Turnover Ratio154.13BMarket Cap2Fall151.91BFloat Cap
Constituent Stocks: 10Top Rising: SGMO+10.78%
Sign in to post a comment
$CRISPR Therapeutics (CRSP.US)$ I’M JUST LOADING AS IT GOES DOWN, BRIGHTER DAYS ARE COMING, IF YOUR NOT IN A HURRY, THIS IS A GOOD ONE TO INVEST. TO HAVE THIS BELOW 40 IS ALREADY A BLESSING FOR ANYONE INTERESTED.
3
1
The trading year ended with markets declining
Shortly after close, the $S&P 500 Index (.SPX.US)$ dipped 0.43% to 5,881.63, the $Dow Jones Industrial Average (.DJI.US)$ edged down 0.07% to 42,544.22, and the $Nasdaq Composite Index (.IXIC.US)$ dropped 0.9% to 19,310.79.
For the year, the Nasdaq Composite led the way, rising 29%. The S&P 500 was up 23% (a second straight year of 20% gains) and the Dow added almost 13%.
MACR...
Shortly after close, the $S&P 500 Index (.SPX.US)$ dipped 0.43% to 5,881.63, the $Dow Jones Industrial Average (.DJI.US)$ edged down 0.07% to 42,544.22, and the $Nasdaq Composite Index (.IXIC.US)$ dropped 0.9% to 19,310.79.
For the year, the Nasdaq Composite led the way, rising 29%. The S&P 500 was up 23% (a second straight year of 20% gains) and the Dow added almost 13%.
MACR...
58
4
8
Barclay's keeps overweight and maintains 9 dollar target. Says they assigned limited value to the Hemo A program. Very Intresting
4
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. No buy pressure/momentum- No day t...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours)
7. No buy pressure/momentum- No day t...
73
23
9
$Sangamo Therapeutics (SGMO.US)$ buy buy buy
3
1
$Sangamo Therapeutics (SGMO.US)$ Yup yup! Looks as it could be a swing opportunity? I dont think the news warrants this type of drop? Ifn there was a bunch sitting on the sidelines looking for a lower in? Well they just got it! Hehehe
3
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Sangamo Therapeutics (SGMO.US)$ Sangamo Says Collaboration, License Agreement With Pfizer On Giroctocogene Fitelparvovec Will Terminate Effective April 21, 2025; Plans To Explore All Options To Commercialize The Asset, Including Seeking Potential New Partner
Benzinga· 4 mins ago
Sangamo believes that its recently announced partnerships with Genentech and Astellas, and advanced business development discussions for its Fabry gene therapy program, will allow it to chart a path forward for its n...
Benzinga· 4 mins ago
Sangamo believes that its recently announced partnerships with Genentech and Astellas, and advanced business development discussions for its Fabry gene therapy program, will allow it to chart a path forward for its n...
No comment yet
mash00 : Today is the day